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Spinal muscular atrophy is a common and often fatal
autosomal recessive disorder for which carrier screen-
ing is available. The Association forMolecular Pathology
has evaluated recent opinions regarding population car-
rier screening, reviewed the current literature, and de-
veloped a position statement that includes specific recom-
mendations addressing both diagnostic and practical
issues that affect implementation. (J Mol Diagn 2011, 13:
3–6; DOI: 10.1016/j.jmoldx.2010.11.012)
Spinal muscular atrophy (SMA, MIM#253300) is the sec-
ond most common fatal autosomal recessive disorder
after cystic fibrosis, affecting approximately 1 in 6000 to
10,000 live births.1,2 It is characterized by hypotonia,
proximal muscle weakness, and respiratory distress due
to degeneration of motor neurons in the spinal cord.
The clinical presentation of SMA is highly variable,
ranging in onset from infancy to adulthood and in severity
from profound hypotonia to minor muscle weakness.
SMA has been classified into four groups based on ageof onset and motor function achieved.3 Type I SMA with
onset of disease symptoms before 6 months of age and
death from respiratory failure within 2 years of life ac-
counts for 60% to 70% of SMA. Type II SMA, which is
characterized by onset of symptoms after 6 months of
age, significant respiratory distress, an inability to stand
or walk unaided, and a variable lifespan, accounts for
20% to 30% of SMA. Types III and IV are milder forms of
SMA with onset of disease during infancy or youth and a
retained ambulatory capacity. These two types account
for the remaining 10% to 20% of SMA.4,5
SMA is caused by mutations in the survival motor neu-
ron 1 (SMN1) gene (Entrez Gene ID number 6606). A
homologous pseudogene of SMN1, called SMN2, lies in
an inverted orientation in cis- with SMN1 on chromosome
5q11-q13. Variations in the number of copies of SMN1
and SMN2 are common. SMN1 and SMN2 differ by just
five nucleotides, only one of which, in exon 7, is within the
coding region. This sequence change affects splicing
and results in much reduced expression levels of full-
length, functional protein from the SMN2 gene. The loss
of both functional copies of the SMN1 gene, most often
The 2010 AMP Clinical Practice Committee consisted of M. Fernanda
Sabato Charreun, Michelle Dolan, Christine A. Curtis, William K. Funk-
houser, Jane Gibson, Neal Lindeman, Ira Lubin, Federico Monzon,
Narasimhan Nagan, Joseph F. Pulliam, Iris Schrijver (Chair), Patrik Vi-
tazka, Jeffrey D. Wisotzkey, Donna M. Wolk, and Belinda Yen-Lieberman.
Accepted for publication July 15, 2010.
K.M. is employed by and has stock options with Quest Diagnostics.
N.N. is employed by and has stock options with Genzyme Corporation.
The views expressed in this article (or position statement) are expressly the
opinion of the authors and do not indicate any position of their employers.
Standard of practice is not being defined by this article, and there may
be alternatives.
Corresponding author: Iris Schrijver, M.D., Department of Pathology,
L235, Stanford University Medical Center, 300 Pasteur Dr., Stanford, CA
94305. E-mail: ischrijver@stanfordmed.org.
Address reprint requests to The Association for Molecular Pathol-
ogy, c/o Mary Williams, 9650 Rockville Pike, Bethesda, MD 20814-
3993. E-mail: mwilliams@asip.org.
3
4 Muralidharan et al
JMD January 2011, Vol. 13, No. 1due to deletion and/or gene conversion of SMN1 to
SMN2, is the main cause of SMA. Such patients retain at
least one copy of the SMN2 gene. An inverse relationship
between the severity of the disease and the number of
SMN2 gene copies in an affected individual has been
observed.6 There are indications of other modifying fac-
tors that influence the phenotypic variability of SMA.
The molecular diagnosis of SMA is accomplished
through the detection of homozygous deletions of SMN1.
The presence of SMN2 and the varying numbers of both
SMN1 and SMN2 complicate molecular testing, but the
sequence differences between the two genes allow them
to be distinguished. More than 95% of SMA patients have
a homozygous deletion of SMN1 exon 7. Approximately
5% of the affected patients carry other rearrangements
and/or point mutations in the SMN1 gene that are not
detected by the deletion assay.
Because SMA is an autosomal recessive disorder, most
parents are unaware of their carrier status until they have an
affected child. Carrier testing of parents of affected individ-
uals, especially those with a known genotype, has been
available for more than a decade. SMA carrier testing can
be performed through assessment of the SMN1 copy num-
ber. Unaffected individuals carry at least one copy of the
telomeric SMN1 gene on chromosome 5 and variable copy
numbers of the centromeric SMN2 gene. The complex SMN
genotypes, which result from duplications and deletions of
SMN1 and SMN2, have been well documented and affect
the accuracy of carrier testing. The occurrence of two cop-
ies of the SMN1 gene on one chromosome 5 and zero
copies on the other (the “2 0” genotype) is recognized as
a source of false-negative carrier testing results. Since ap-
proximately 5% of normal individuals have three copies of
SMN1 overall, the presence of two SMN1 copies on one
chromosome 5 is far from uncommon. SMN1 point muta-
tions are not detectable by current methods of dosage
analysis and present another potential source of false-neg-
ative carrier test results.4 Finally, even for couples with one
identified carrier, SMA has a relatively high de novomutation
rate,5 with de novo rearrangements found in approximately
2% of indexed patients.7
Incidence and prevalence of clinically typical SMA sug-
gest a positive diagnosis in approximately one in every
10,000 live births and a carrier frequency of about one in 50.
However, carrier testing data from more than 1200 unaf-
fected individuals without a family history suggest a carrier
frequency of approximately one in 38,8 which extrapolates
to an incidence of around one in 6000 live births under
Hardy-Weinberg equilibrium. There are several possible
explanations for this discrepancy, including chance variation
and/or embryonic lethality of some severely affected con-
ceptuses. It has been hypothesized that an important con-
tributor to this discrepancy may be the occurrence of clin-
ically atypical SMA caused by homozygous deletion of the
SMN1 gene.5
Background to Practice Recommendations
The American College of Medical Genetics has issued a
practice guideline on carrier screening for SMA, recom-mending that SMA carrier testing be offered to all couples,
regardless of race or ethnicity, to allow carriers to make
informed reproductive choices (http://www.acmg.net/
AM/Template.cfm?SectionPractice_Guidelines, last ac-
cessed August 15, 2010).4 The American College of
Medical Genetics contends that SMA meets the criteria
for population-based carrier screening by virtue of its
clinical severity and high carrier frequency, and because
of the availability of reliable assays for carrier and prena-
tal testing. The American College of Obstetricians and
Gynecologists (ACOG, now called the American Con-
gress of Obstetricians and Gynecologists) committee on
genetics published an opinion that preconception and
prenatal screening for SMA in the general population is
premature at this time. ACOG recommended that SMA
carrier screening should be offered to patients with a
family history of SMA.9 While acknowledging that SMA
meets some of the common criteria for population-based
screening, the ACOG asserts that specific issues re-
main to be addressed before implementation. These
issues include the critical assessment of pilot screen-
ing studies, determination of best practices for pre-
and posttest education and counseling, analyses of
cost effectiveness, development of educational mate-
rials for patients and physicians, and laboratory stan-
dards for testing and reporting.
Practice guidelines serve the purpose of bridging the
gap between research and practice.10 They guide clini-
cal practice, frequently serve as the main source of in-
formation for health care providers, patients, and other
stakeholders, and influence the development and mar-
keting of diagnostics and drugs. However, the formula-
tion of evidence-based guidelines is complex. Apart from
the critical evaluation of available information and its
translation into recommendations, the creation of such
guidelines requires a process in which risks and benefits,
cost, and the capacity and ability of the health care
system to implement the recommendations must be as-
sessed. In disease conditions that involve different med-
ical disciplines, it is not unusual to encounter guidelines
with different positions. With collaboration, discussion,
and clarification, guidelines can evolve over time and
culminate in a consensus practice that balances risk,
cost, and patient benefit.
In the context of the differing positions of the Amer-
ican College of Medical Genetics and ACOG on pop-
ulation-based carrier screening for SMA, the Associa-
tion for Molecular Pathology (AMP) has evaluated the
issues and developed a position statement to include
specific recommendations for population-based car-
rier screening for SMA.
Position Statement and Specific
Recommendations
Position Statement
AMP recognizes the utility of SMA carrier screening given
the high incidence and severe nature of this condition.
Furthermore, the advances in our knowledge about SMA
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SMA carriers place us at the threshold of feasibility of
population-based carrier screening for SMA. AMP rec-
ommends that implementation of SMA carrier testing be
performed in a step-wise fashion and that the following
critical issues be actively and expeditiously explored,
pursued, and resolved before full implementation.
Specific Recommendations
1. Organize Community Involvement to Identify
Issues, Set Priorities, and Develop Solutions
Cystic fibrosis carrier screening is an example of recently
implemented population-based carrier screening. Using
this as a model, AMP recommends meetings to engage
medical (clinical and laboratory) experts and other inter-
ested parties, such as parent groups, researchers, health
care providers, ethicists, and payers, to identify issues,
set priorities, and develop solutions. One way to facilitate
such meetings would be the formation of an advisory
committee on carrier screening for heritable disorders
that is analogous to the Advisory Committee on Heritable
Diseases in Newborns and Children for newborn screen-
ing. This will enable the development of a well-defined
plan for implementation of population carrier screening
for SMA.
2. Pilot Programs before General Implementation
Before full implementation, SMA population-based
screening pilot programs should first be offered in clearly
delineated, perhaps statewide, programs. A recently
published population-based SMA carrier screening pilot
study demonstrated that i) the majority of patients
(98.7%) who pursued SMA carrier testing remained fa-
vorable regarding this testing following disclosure of the
results, ii) despite a lack of familiarity with SMA, there is
interest in carrier screening for this condition, and iii) the
information necessary for individuals to make informed de-
cisions regarding carrier testing for SMA can be presented
effectively and efficiently through counseling session(s) and
printed educational material, such as those provided by
patient advocacy groups such as the Claire Altman Heine
Foundation, Inc. and Prevention of Spinal Muscular Atro-
phy (CAHF, http://www.clairealtmanheinefoundation.org/,
last accessed August 15, 2010).11 Because this is the
first reported study that included patient knowledge, at-
titudes, and assessment of existing education material,
future pilot programs should be designed to gather ad-
ditional data on carrier rates, refine risk estimates, opti-
mize result reports, and develop educational materials for
physicians and patients to facilitate pre- and posttest
counseling. Development of educational materials and
testing such material is a currently unmet prerequisite. An
understanding of carrier status should be assessed im-
mediately after screening and at a later point, to evaluate
the accuracy of recollection of the meaning and signif-
icance of the results received. This will be a valuable
tool in the assessment of feasibility, utility, and value of
population carrier screening under various models.3. Determine SMA Carrier Frequency in Different
Ethnic Groups
Ethnicity-specific information on SMA carrier frequencies
is limited. Although SMA occurs in all populations, the
carrier frequency in different ethnic groups appears to
differ significantly. A recent study on SMA carrier fre-
quencies12 indicates significant differences among the
major ethnic groups of the United States, ranging from
about 1 in 35 in whites to about 1 in 66 in African Amer-
icans, which could possibly be due to a chance variation.
Replicative, large-scale, population-based studies are
required to minimize sampling error and establish carrier
frequencies among various ethnic populations.
4. Continue Research on SMA Genotype–Phenotype
Correlations
Currently, accurate prediction of the phenotype of a fetus
with a homozygous deletion of SMN1 is not possible
because an understanding of the molecular basis of the
different types of SMA is incomplete and our ability to
predict the severity of the disease, based on genotype, is
limited. It has become clear that the phenotype is not only
modulated by SMN2 copy number, but also by sequence
differences between SMN2 genes.13 As with other disor-
ders for which carrier screening has been implemented,
continued research will be needed to better define geno-
type–phenotype correlations as well as gene–environ-
ment interactions that possibly influence the phenotype.
This research should continue past the implementation of
carrier screening and should inform these programs as
more knowledge of the relationship between genotype
and phenotype becomes available. Such an approach
has proven to be successful for cystic fibrosis.
5. Improve SMA Risk Assessment
In contrast to carrier screening for other conditions such
as those associated with Ashkenazi Jewish ancestry or
cystic fibrosis, the interpretation of SMA carrier testing is
much more complex. Risk assessment of SMA (regard-
less of severity) is complicated by the presence of SMN
copy number variations, small intragenic mutations, a
relatively high de novomutation rate, and the risk of false-
negative carrier screening.14 In addition, there is a pau-
city of data on the distribution of various disease and
normal alleles in different ethnic groups. A particular
challenge is that test results on additional family mem-
bers can drastically change risk estimates for family
members already tested. Genetic counselors, geneti-
cists, and/or molecular diagnosticians who estimate car-
rier risks based on initial test results will need to be
informed of all additional test results so that risk assess-
ments can be adjusted accordingly. For families without a
history of SMA, specific algorithms must be developed to
enable consistent and correct risk estimates. Currently,
expert evaluation that results in accurate carrier risk as-
sessment is not widely available. This knowledge base
and expertise must be integrated as part of the imple-
mentation of population carrier screening for SMA.
6 Muralidharan et al
JMD January 2011, Vol. 13, No. 16. Address SMA Carrier Test Licensing and
Accessibility
Laboratory testing is of primary importance for popula-
tion-based SMA carrier screening. Testing for cystic fi-
brosis and Ashkenazi Jewish disease carrier status is
widely available and performed in numerous laboratories.
Carrier testing for SMA, on the other hand, is (nationally)
only available from very few laboratories due to licensing
issues. A test used for population-based screening, par-
ticularly screening advocated by professional organiza-
tions, should support widespread accessibility to pa-
tients, robust capacity, effective proficiency testing,
continued innovation, and competitive pricing. Whether
SMA carrier testing, as currently available, would meet
such goals for a generalized population-based carrier
screening is questionable. Although AMP/American Civil
Liberty Union’s actions against gene patenting may re-
solve this issue in the future, concerns about accessibility
and affordability of the test need to be seriously consid-
ered at the present time. Meanwhile, the absence of
nonexclusive licenses for any lab that wishes to pay the
fees remains an ethical dilemma.
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